Skip to main content
. 2018 Sep 27;7(11):5448–5456. doi: 10.1002/cam4.1794

Figure 2.

Figure 2

A, The tumor‐free survival rate of radioiodine refractory (RAIR) patients was significantly lower than that of non‐RAIR patients (P = 0.002). B, The overall survival of RAIR patients was significantly lower than that of non‐RAIR patients (P = 0.011)